Clinical Trials Details

A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with Metastatic Castrate Resistant Prostate Cancer (MCRPC), Stratified by Aggressive Variant Signature

IRB Protocol Number

SWOG 2312

Clinical Trial Categories

• Prostate Cancer

Contact

Clinical Trials at 910-715-2200

How to Participate

Eligibility: 

Men, ages 18 and older with castrate-resistant prostate cancer and metastatic disease by bone scan and/or CT/MRI. May have received any prior therapy, but one must be docetaxel or contain docetaxel in either the castrate-sensitive and/or castrate resistant disease state and must have experienced progressive disease after prior therapy.